If a woman has not had a thrombotic event in years of use she is unlikely to have one now

doi:10.1136/bmj.311.7020.1638c

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

John Guillebaud

Professor of family planning and reproductive health Margaret Pyke Family Planning Centre, London W1P 1LB

EDITOR,--My editorial commenting on the letter from the Committee on Safety of Medicines and the three studies that gave rise to it had to be cut because of lack of space.1 In the original version I argued that, in these trials, the proportion of women who had been exposed in the past to ethinyloestradiol (in any combination) might be higher among current users of the third generation pills containing desogestrel and gestodene; ethinyloestradiol is still recognised as the prime prothrombotic constituent of …